Fitness News
Asthma Allergy News
Diabetes News
Women's Health News
 > Men's Health News

Personal Archive
My Account

About Us
Advertise With Us
Feed Your Site
Contact Us

Site Map
RSS News Feed 

  Website development & hosting
   by Cyber Software Solutions

AACR: Long-Term Selenium Intake Tied to Prostate Cancer
Decrease in advanced disease risk is associated with increasing quintiles of toenail mineral

WEDNESDAY, April 10 (HealthDay News) -- Toenail selenium, which reflects long-term selenium intake, is associated with a decrease in the risk of advanced prostate cancer, especially during later follow-up, according to a study presented at the annual meeting of the American Association for Cancer Research, held April 6 to 10 in Washington, D.C.

Milan S. Geybels, from Maastrich University in the Netherlands, and colleagues examined the correlation between toenail selenium and the risk of advanced prostate cancer using data from 58,279 men, aged 55 to 69 years, from the Netherlands Cohort study. A total of 898 cases of advanced prostate cancer were identified during 17.3 years of follow-up.

The researchers found that the risk of advanced prostate cancer was reduced with increasing quintiles of toenail selenium (hazard ratios, 1.00 [reference], 0.69, 0.45, 0.32, and 0.24; P for trend < 0.01). For men diagnosed during later follow-up, the correlation was more pronounced, with adjusted hazard ratios of 0.91 for men diagnosed at less than six years; 0.85 for men diagnosed at six to 12 years; and 0.77 for men diagnosed after more than 12 years of follow-up.

"Our findings need to be replicated in further prospective studies, with an extended follow-up for the assessment of incident advanced prostate cancer, and with a wide range of toenail selenium that includes low selenium levels," Geybels said in a statement. "If our results can be confirmed, a prevention trial of selenium and prostate cancer in a low-selenium population may be justified."

Press Release
More Information

Health News Copyright © 2013 HealthDay. All rights reserved.

Back to Top Stories